ENSG00000173821 |
|
Merkel cell skin cancer |
sequence_alteration |
10.0% (3/30) |
1 entry |
ENSG00000173821 |
|
colorectal adenocarcinoma |
stop_gained |
10.27% (137/1334) |
2 entries |
ENSG00000173821 |
|
cecum adenocarcinoma |
missense_variant |
6.061% (8/132) |
1 entry |
ENSG00000173821 |
|
gastric adenocarcinoma |
sequence_alteration |
4.86% (33/679) |
1 entry |
ENSG00000173821 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
3.892% (49/1259) |
2 entries |
ENSG00000173821 |
|
esophageal adenocarcinoma |
sequence_alteration |
7.306% (32/438) |
1 entry |
ENSG00000173821 |
|
skin melanoma |
sequence_alteration |
3.922% (38/969) |
2 entries |
ENSG00000173821 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
8.235% (7/85) |
1 entry |
ENSG00000173821 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
5.063% (4/79) |
1 entry |
ENSG00000173821 |
|
colon adenocarcinoma |
missense_variant |
6.389% (49/767) |
8 entries |
ENSG00000173821 |
|
lung adenocarcinoma |
sequence_alteration |
3.268% (40/1224) |
1 entry |
ENSG00000173821 |
|
breast carcinoma |
missense_variant |
2.268% (32/1411) |
2 entries |
ENSG00000173821 |
|
gastric adenocarcinoma |
missense_variant |
4.86% (33/679) |
3 entries |
ENSG00000173821 |
|
clear cell renal carcinoma |
missense_variant |
1.394% (18/1291) |
3 entries |
ENSG00000173821 |
|
brain glioblastoma |
sequence_alteration |
0.9709% (9/927) |
2 entries |
ENSG00000173821 |
|
skin melanoma |
missense_variant |
3.922% (38/969) |
4 entries |
ENSG00000173821 |
|
colon adenocarcinoma |
sequence_alteration |
6.389% (49/767) |
4 entries |
ENSG00000173821 |
|
hemangioblastoma |
sequence_alteration |
15.62% (5/32) |
1 entry |
ENSG00000173821 |
|
brain glioblastoma |
missense_variant |
0.9709% (9/927) |
2 entries |
ENSG00000173821 |
|
basal cell carcinoma |
missense_variant |
6.897% (4/58) |
1 entry |
ENSG00000173821 |
|
prostate adenocarcinoma |
missense_variant |
6.396% (93/1454) |
1 entry |
ENSG00000173821 |
|
rectal adenocarcinoma |
missense_variant |
3.524% (8/227) |
1 entry |
ENSG00000173821 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
3.976% (27/679) |
1 entry |
ENSG00000173821 |
|
colorectal adenocarcinoma |
missense_variant |
10.27% (137/1334) |
5 entries |
ENSG00000173821 |
|
colorectal adenocarcinoma |
conservative_inframe_deletion |
10.27% (137/1334) |
1 entry |
ENSG00000173821 |
|
hepatocellular carcinoma |
missense_variant |
3.315% (30/905) |
2 entries |
ENSG00000173821 |
|
acute myeloid leukemia |
missense_variant |
0.9891% (10/1011) |
2 entries |
ENSG00000173821 |
|
melanoma |
sequence_alteration |
9.804% (10/102) |
2 entries |
ENSG00000173821 |
|
colorectal adenocarcinoma |
sequence_alteration |
10.27% (137/1334) |
1 entry |
ENSG00000173821 |
|
Cervical Small Cell Carcinoma |
missense_variant |
33.33% (2/6) |
1 entry |
ENSG00000173821 |
|
melanoma |
missense_variant |
9.804% (10/102) |
2 entries |
ENSG00000173821 |
|
Ampulla of Vater Carcinoma |
missense_variant |
4.706% (4/85) |
1 entry |
ENSG00000173821 |
|
diffuse large B-cell lymphoma |
missense_variant |
2.295% (7/305) |
4 entries |
ENSG00000173821 |
|
ovarian serous adenocarcinoma |
missense_variant |
2.08% (14/673) |
2 entries |
ENSG00000173821 |
|
small cell lung carcinoma |
missense_variant |
2.477% (8/323) |
3 entries |
ENSG00000173821 |
|
diffuse gastric adenocarcinoma |
missense_variant |
5.063% (4/79) |
2 entries |
ENSG00000173821 |
|
oral squamous cell carcinoma |
missense_variant |
4.265% (9/211) |
4 entries |
ENSG00000173821 |
|
prostate carcinoma |
missense_variant |
3.696% (18/487) |
4 entries |
ENSG00000173821 |
|
squamous cell lung carcinoma |
sequence_alteration |
3.684% (34/923) |
2 entries |
ENSG00000173821 |
|
prostate carcinoma |
sequence_alteration |
3.696% (18/487) |
1 entry |
ENSG00000173821 |
|
osteosarcoma |
sequence_alteration |
1.695% (2/118) |
1 entry |
ENSG00000173821 |
|
esophageal squamous cell carcinoma |
missense_variant |
3.976% (27/679) |
6 entries |
ENSG00000173821 |
|
squamous cell lung carcinoma |
stop_gained |
3.684% (34/923) |
1 entry |
ENSG00000173821 |
|
female breast carcinoma |
missense_variant |
1.79% (7/391) |
3 entries |
ENSG00000173821 |
|
female breast carcinoma |
sequence_alteration |
1.79% (7/391) |
1 entry |
ENSG00000173821 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.796% (3/167) |
1 entry |
ENSG00000173821 |
|
non-small cell lung carcinoma |
missense_variant |
8.065% (5/62) |
3 entries |
ENSG00000173821 |
|
colon adenocarcinoma |
frameshift_variant |
6.389% (49/767) |
2 entries |
ENSG00000173821 |
|
skin melanoma |
stop_gained |
3.922% (38/969) |
2 entries |
ENSG00000173821 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
3.892% (49/1259) |
1 entry |
ENSG00000173821 |
|
bladder transitional cell carcinoma |
missense_variant |
2.92% (4/137) |
3 entries |
ENSG00000173821 |
|
breast carcinoma |
sequence_alteration |
2.268% (32/1411) |
1 entry |
ENSG00000173821 |
|
colorectal adenocarcinoma |
frameshift_variant |
10.27% (137/1334) |
3 entries |
ENSG00000173821 |
|
breast ductal adenocarcinoma |
missense_variant |
11.81% (71/601) |
2 entries |
ENSG00000173821 |
|
prostate adenocarcinoma |
sequence_alteration |
6.396% (93/1454) |
2 entries |
ENSG00000173821 |
|
squamous cell lung carcinoma |
missense_variant |
3.684% (34/923) |
3 entries |
ENSG00000173821 |
|
lung adenocarcinoma |
missense_variant |
3.268% (40/1224) |
5 entries |
ENSG00000173821 |
|
chronic lymphocytic leukemia |
sequence_alteration |
0.6757% (6/888) |
1 entry |
ENSG00000173821 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
8.235% (7/85) |
2 entries |
ENSG00000173821 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
7.692% (14/182) |
2 entries |
ENSG00000173821 |
|
lung adenocarcinoma |
stop_gained |
3.268% (40/1224) |
1 entry |
ENSG00000173821 |
|
small cell lung carcinoma |
stop_gained |
2.477% (8/323) |
1 entry |
ENSG00000173821 |
|
bladder transitional cell carcinoma |
sequence_alteration |
2.92% (4/137) |
1 entry |
ENSG00000173821 |
|
esophageal adenocarcinoma |
conservative_inframe_deletion |
7.306% (32/438) |
1 entry |
ENSG00000173821 |
|
angioimmunoblastic T-cell lymphoma |
sequence_alteration |
1.075% (1/93) |
1 entry |
ENSG00000173821 |
|
angiosarcoma |
sequence_alteration |
7.143% (1/14) |
1 entry |
ENSG00000173821 |
|
prostate carcinoma |
frameshift_variant |
3.696% (18/487) |
1 entry |
ENSG00000173821 |
|
adrenal cortex carcinoma |
missense_variant |
0.6098% (1/164) |
1 entry |
ENSG00000173821 |
|
Breast Diffuse Large B-Cell Lymphoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000173821 |
|
bile duct adenocarcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000173821 |
|
Ampulla of Vater Carcinoma |
stop_gained |
4.706% (4/85) |
1 entry |
ENSG00000173821 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.3195% (2/626) |
1 entry |
ENSG00000173821 |
|
esophageal adenocarcinoma |
missense_variant |
7.306% (32/438) |
1 entry |
ENSG00000173821 |
|
Pleural Mesothelioma |
missense_variant |
1.031% (1/97) |
1 entry |
ENSG00000173821 |
|
rectal adenocarcinoma |
stop_gained |
3.524% (8/227) |
1 entry |
ENSG00000173821 |
|
Uterine Carcinosarcoma |
missense_variant |
6.364% (7/110) |
1 entry |
ENSG00000173821 |
|
hemangioblastoma |
missense_variant |
15.62% (5/32) |
1 entry |
ENSG00000173821 |
|
laryngeal squamous cell carcinoma |
missense_variant |
3.846% (1/26) |
1 entry |
ENSG00000173821 |
|
embryonal rhabdomyosarcoma |
sequence_alteration |
1.266% (1/79) |
1 entry |
ENSG00000173821 |
|
Pleural Sarcomatoid Mesothelioma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000173821 |
|
Spinal Cord Astrocytoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000173821 |
|
HER2 Positive Breast Carcinoma |
frameshift_variant |
7.692% (14/182) |
1 entry |
ENSG00000173821 |
|
non-small cell lung carcinoma |
stop_gained |
8.065% (5/62) |
1 entry |
ENSG00000173821 |
|
Adamantinomatous Craniopharyngioma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000173821 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
2.299% (2/87) |
1 entry |
ENSG00000173821 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
1.064% (1/94) |
1 entry |
ENSG00000173821 |
|
hepatocellular carcinoma |
frameshift_variant |
3.315% (30/905) |
1 entry |
ENSG00000173821 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
0.2632% (1/380) |
1 entry |
ENSG00000173821 |
|
Merkel cell skin cancer |
missense_variant |
10.0% (3/30) |
1 entry |
ENSG00000173821 |
|
esophageal squamous cell carcinoma |
stop_gained |
3.976% (27/679) |
1 entry |
ENSG00000173821 |
|
medullary thyroid gland carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000173821 |
|
ovarian serous adenocarcinoma |
frameshift_variant |
2.08% (14/673) |
1 entry |
ENSG00000173821 |
|
acute lymphoblastic leukemia |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000173821 |
|
lung carcinoid tumor |
sequence_alteration |
18.18% (2/11) |
1 entry |
ENSG00000173821 |
|
squamous cell lung carcinoma |
frameshift_variant |
3.684% (34/923) |
1 entry |
ENSG00000173821 |
|
pseudomyxoma peritonei |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000173821 |
|
multiple myeloma |
stop_gained |
2.273% (1/44) |
1 entry |
ENSG00000173821 |
|
large cell lung carcinoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000173821 |
|
oral squamous cell carcinoma |
frameshift_variant |
4.265% (9/211) |
1 entry |
ENSG00000173821 |
|
alveolar rhabdomyosarcoma |
missense_variant |
1.695% (1/59) |
1 entry |
ENSG00000173821 |
|
mucosal melanoma |
sequence_alteration |
7.143% (1/14) |
1 entry |
ENSG00000173821 |
|
basal cell carcinoma |
sequence_alteration |
6.897% (4/58) |
1 entry |
ENSG00000173821 |
|
anaplastic astrocytoma |
missense_variant |
2.174% (1/46) |
1 entry |
ENSG00000173821 |
|
brain glioblastoma |
frameshift_variant |
0.9709% (9/927) |
1 entry |
ENSG00000173821 |
|
lung carcinoid tumor |
missense_variant |
18.18% (2/11) |
1 entry |
ENSG00000173821 |
|
small cell lung carcinoma |
sequence_alteration |
2.477% (8/323) |
1 entry |
ENSG00000173821 |
|
lung adenocarcinoma |
frameshift_variant |
3.268% (40/1224) |
1 entry |
ENSG00000173821 |
|
breast ductal adenocarcinoma |
stop_gained |
11.81% (71/601) |
1 entry |
ENSG00000173821 |
|
metaplastic breast carcinoma |
missense_variant |
1.961% (1/51) |
1 entry |
ENSG00000173821 |
|
Gallbladder Adenocarcinoma |
missense_variant |
2.299% (2/87) |
1 entry |
ENSG00000173821 |
|
Spinal Cord Astrocytoma |
sequence_alteration |
25.0% (1/4) |
1 entry |
ENSG00000173821 |
|
multiple myeloma |
missense_variant |
2.273% (1/44) |
1 entry |
ENSG00000173821 |
|
Ampulla of Vater Carcinoma |
conservative_inframe_deletion |
4.706% (4/85) |
1 entry |
ENSG00000173821 |
|
female breast carcinoma |
frameshift_variant |
1.79% (7/391) |
1 entry |
ENSG00000173821 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
3.976% (27/679) |
1 entry |
ENSG00000173821 |
|
head and neck squamous cell carcinoma |
frameshift_variant |
0.3195% (2/626) |
1 entry |